Avian flu fears increase Tamiflu demand

Share this article:

As governments stockpile Roche's Tamiflu to prevent a possible avian flu pandemic, consumer demand is rising too, USA Today reports.
Market researcher Verispan says U.S. prescriptions for Tamiflu hit 34,388 for the week ending Oct. 7, up 713 percent from the same period last year.
Drugstore.com, told the newspaper that it has sold more Tamiflu in the past five weeks than in the last six months of last year. "Demand is off the charts," a spokesman for the company said.
The U.S. has stockpiled enough anti-virals to treat 1 percent of the population and recently announced plans to get enough to treat 20 million people. Switzerland-based Roche, which doubled manufacturing capacity in 2004, will double it again this year, launch some manufacturing in the U.S. and add more capacity next year, the firm said.
Meanwhile, GlaxoSmithKline said it is making more of its anti-viral treatment Relenza. The U.S. government is buying 84,300 treatments.
Through the first half of 2005, Tamiflu sales hit $450 million, Roche said, compared with $255 million for all of 2004. Relenza sales in 2004 were $5.5 million.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...